Enzo Biochem Inc

NYSE ENZ

Download Data

Enzo Biochem Inc EBIT to Total Assets Ratio 3 year CAGR for the year ending July 31, 2023: -16.69%

Enzo Biochem Inc EBIT to Total Assets Ratio 3 year CAGR is -16.69% for the year ending July 31, 2023. The EBIT to Total Assets Ratio measures a company's operating earnings (EBIT) generated per dollar of total assets. It shows how efficiently a company utilizes its assets to generate earnings. A higher ratio indicates better asset utilization and profitability. It reflects the ability of a company to generate earnings from its invested assets and is useful in assessing operational efficiency and financial performance. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Enzo Biochem Inc EBIT to Total Assets Ratio for the year ending July 31, 2022 was -0.16, a -286.19% change year over year.
  • Enzo Biochem Inc EBIT to Total Assets Ratio for the year ending July 31, 2021 was 0.09, a 141.36% change year over year.
  • Enzo Biochem Inc EBIT to Total Assets Ratio for the year ending July 31, 2020 was -0.21, a -128.67% change year over year.
  • Enzo Biochem Inc EBIT to Total Assets Ratio for the year ending July 31, 2019 was 0.73, a -26.68% change year over year.
NYSE: ENZ

Enzo Biochem Inc

CEO Mr. Hamid Erfanian
IPO Date June 12, 1980
Location United States
Headquarters 81 Executive Blvd., Farmingdale, NY, United States, 11735
Employees 179
Sector Healthcare
Industry Diagnostics & research
Description

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Similar companies

FONR

Fonar Corporation

NA

NA

SERA

Sera Prognostics Inc

NA

NA

OLK

Olink Holding AB ADR

NA

NA

DRIO

DarioHealth Corp

NA

NA

XGN

Exagen Inc

NA

NA

BDSX

Biodesix Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email